
|Slideshows|December 19, 2018
Impact of Canagliflozin on Renoprotection in T2DM
Author(s)Veronica Hackethal MD
Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD
4
What Comes Next for Berobenatide? VESPER-3 and Phase 3 Expectations, With John Buse, MD, PhD
5


























































